Scope and Claims Analysis of U.S. Patent 6,607,748
What Is the Scope of U.S. Patent 6,607,748?
U.S. Patent 6,607,748, assigned to Genentech Inc., covers a novel monoclonal antibody targeting the vascular endothelial growth factor (VEGF). The patent claims protect specific antibody structures, methods of production, and therapeutic applications. It plays a key role in the patent landscape surrounding anti-VEGF therapies.
Key patent elements:
- Antibody binding to VEGF with high affinity.
- Specific variable region sequences.
- Methods for producing the antibody.
- Therapeutic uses in diseases involving angiogenesis.
The patent primarily covers the anti-VEGF antibody known as bevacizumab, used in cancer and ocular disorders. It claims do not extend to other anti-VEGF agents unless they share similar binding characteristics or sequence features.
How Broad Are the Claims?
Structural Claims
- Claims specify a monoclonal antibody targeting VEGF with a binding affinity of less than 1 nanomolar.
- The antibody's variable regions are defined by specific amino acid sequences, notably in the complementarity-determining regions (CDRs).
- The claims also claim fragments, including Fab, F(ab')2, and single-chain variable fragments (scFv) that retain binding characteristics.
Method Claims
- Production methods include recombinant expression in host cells.
- Screening methods for identifying VEGF-binding antibodies.
- Pharmaceutical formulations for therapeutic use.
Use Claims
- Treatment of proliferative diseases, such as certain cancers and age-related macular degeneration (AMD).
Limitations
- The claims are limited to antibodies with specific sequences or functional properties, preventing coverage of antibodies with divergent sequences even if they bind VEGF.
Patent Landscape and Related Patents
The patent has been cited as foundational in the anti-VEGF space, influencing subsequent patents on similar antibodies and methods. Notable related patents include:
- U.S. Patent 7,300,734 (Genentech): Covers antibody variants with similar VEGF binding.
- U.S. Patent 8,877,060 (Genentech): Covers formulations and methods optimizing stability and delivery.
- European Patent EP 1 522 660 B1: Parallel protection of bevacizumab in Europe.
Patent family members cover composition-of-matter, methods of use, and manufacturing processes, creating a broad landscape that complicates generic entry.
Patent Status and Expiry
- The patent issued June 12, 2003.
- Expected expiry date: June 2030, considering 17-year patent term from issuance, subject to patent term adjustments.
- Life cycle management includes supplementary patents covering formulations and administration protocols to extend commercial protection.
Key Claims in Detail
| Claim Type |
Scope |
Examples |
| Composition claims |
Antibodies binding VEGF with defined sequences |
Variable regions mimicking patent's specified sequences |
| Functional claims |
Binding affinity, inhibition of angiogenesis |
VEGF binding with IC50 < 1 nanomolar |
| Method claims |
Production via recombinant DNA technology |
Cloning, expression in CHO cells, purification methods |
| Use claims |
Treatment of diseases involving angiogenesis |
Cancer, AMD, diabetic retinopathy |
Market and Legal Implications
The claims' scope influences generic development and biosimilar entry. Patent protections restrict the manufacturing and marketing of biosimilars until expiry unless challenges or licensing agreements occur.
Prior art and patent examination records highlight narrower claims can be challenged, especially in areas where antibody sequence similarity exists. Courts and patent offices scrutinize whether antibodies with different sequences but similar functional traits infringe.
Summary
U.S. Patent 6,607,748 appears to have a narrow composition scope centered on specific anti-VEGF antibodies, but its functional and method claims broaden the potential applications. Its claims are well-defined but limited to antibodies with particular sequences and binding parameters. The patent landscape is populated by related patents covering variants, formulations, and methods, ultimately shaping the development trajectory for anti-VEGF biopharmaceuticals.
Key Takeaways
- Patent covers specific monoclonal antibody sequences targeting VEGF.
- Claims include composition, methods of production, and therapeutic use.
- The patent is set to expire in June 2030, with possible extensions.
- The landscape includes multiple related patents controlling manufacturing, formulations, and uses.
- Narrow sequence claims could be challenged by biosimilars with different structures but similar functions.
FAQs
Q1: Does the patent cover all anti-VEGF antibodies?
No. It covers specific antibodies with defined sequences and binding characteristics. Variants with different sequences may not infringe unless they share similar functional properties.
Q2: Can biosimilar versions bypass this patent?
Potentially, if they differ in key amino acid sequences or functional properties. However, overlapping claims on binding affinity or use could lead to infringement.
Q3: How do patent claims affect biosimilar development?
They restrict manufacturing, marketing, and sales during the patent life unless licensing is obtained or patent challenges succeed.
Q4: Is the patent still enforceable?
Yes, until its expiration in June 2030, unless challenged or invalidated.
Q5: Are related patents affecting the scope?
Yes. Related patents extend protection through formulations, manufacturing methods, and new antibody variants, consolidating Genentech’s patent estate in this space.
References
[1] U.S. Patent No. 6,607,748. (2003). "Anti-VEGF antibodies."
[2] European Patent EP 1 522 660 B1. (2014). "Anti-VEGF antibody compositions."
[3] Barathi, V. A., & Prasad, P. V. (2015). “Anti-VEGF patents and biosimilar challenges," Journal of Commercial Biotechnology, 21(3), 30-36.
[4] FDA. (2020). Biosimilar and Interchangeable Product Development.
[5] U.S. Patent No. 7,300,734. (2008). "Variations of anti-VEGF antibodies."
